Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Proficio Capital Partners LLC raised its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 100.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Proficio Capital Partners LLC’s holdings in 4D Molecular Therapeutics were worth $111,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. State Street Corp grew its holdings in shares of 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after buying an additional 37,232 shares during the period. Redmile Group LLC lifted its holdings in 4D Molecular Therapeutics by 17.6% during the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after acquiring an additional 188,655 shares in the last quarter. Braidwell LP grew its stake in 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after acquiring an additional 855,990 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth about $806,000. Finally, Barclays PLC increased its holdings in shares of 4D Molecular Therapeutics by 141.0% in the third quarter. Barclays PLC now owns 114,848 shares of the company’s stock worth $1,241,000 after acquiring an additional 67,202 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on FDMT. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Bank of America cut their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Chardan Capital dropped their price objective on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Finally, Royal Bank of Canada reduced their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.63.

4D Molecular Therapeutics Trading Up 3.2 %

Shares of FDMT stock opened at $4.24 on Thursday. The firm’s fifty day moving average price is $4.97 and its two-hundred day moving average price is $8.00. 4D Molecular Therapeutics, Inc. has a 1 year low of $3.73 and a 1 year high of $36.25. The firm has a market capitalization of $196.32 million, a P/E ratio of -1.49 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). As a group, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.